NEW YORK (GenomeWeb) – South Korean genomic services provider Macrogen announced today that it has acquired a non-exclusive research tool license to CRISPR-Cas9 technology from the Broad Institute.

Macrogen said that it intends to use the genome-editing technology to build preclinical animal models and for target treatment function analysis to advance precision medicine and gene therapy research and development.

Specific terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.